Direct compression of the (1S)-4,5-dimethoxy-1-[(methylamino)methyl]benzocyclobutane hydrochloride salt on a high-speed rotary tablet press fitted with precompression rollers is conducted only when the API particle size distribution, excipient morphology, and lubricant contact time have been fixed within narrow limits. A representative low-dose dry blend is prepared at 3.5% w/w API, 48.0% w/w microcrystalline cellulose PH102, 44.0% w/w anhydrous lactose, 3.0% w/w crospovidone, 1.0% w/w colloidal silicon dioxide, and 0.5% w/w magnesium stearate. Particle size of the API is confirmed by laser diffraction in accordance with ISO 13320:2020, with a target d90 not greater than 125 µm and span not exceeding 1.8. The pre-lubricant blend is mixed in a 600 L bin blender at 10 rpm for 20 min; magnesium stearate is then added and blended for 3 min at 8 rpm. Lubricant contact beyond 5 min reduces tablet tensile strength and dissolution rate because hydrophobic film coverage increases, a failure mode observed on rotary press lines as increased ejection force variability and sticking at the lower punch. Compression is performed with 10.0 mm round flat-faced bevelled tooling at a turret speed of 40–60 rpm, main compression force 8.0–14.0 kN, and precompression force 2.5–4.0 kN. Tablet hardness is held between 60 N and 100 N, thickness between 2.8 mm and 3.2 mm, and friability not more than 1.0% by USP <1216>. Content uniformity is tested by USP <905> with acceptance value not more than 15.0. Dissolution is run by USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid, with sampling at 5, 10, 15, 30, and 45 min; the immediate-release criterion is normally set at Q = 80% at 30 min unless a controlled-release profile is justified by pharmacokinetic data. The terminal product is an immediate-release tablet that must remain stable for assay, related substances, and chiral purity under ICH Q1A(R2) storage conditions; chiral purity is controlled by a validated HPLC method with a chiral stationary phase, and the release limit is not less than 98.0% enantiomeric excess unless a public pharmacopoeial monograph specifies otherwise. Published data for this specific configuration is limited when the tablet contains the hydrochloride salt at high drug load; in such cases, the formulation is generally switched to dry granulation to avoid segregation and electrostatic charging induced by a high proportion of a low-bulk-density amine salt.

What Changes When the Hydrochloride Salt Is Roller Compacted Before Capsule Filling?

Roller compaction is substituted for direct compression when the hydrochloride salt is present at 8.0% w/w to 20.0% w/w and the direct blend cannot sustain a mass flow rate sufficient for high-speed capsule filling. The dry granulation formulation contains 8.0% w/w API, 40.0% w/w microcrystalline cellulose PH102, 42.0% w/w anhydrous dibasic calcium phosphate, 6.0% w/w croscarmellose sodium, 2.5% w/w hydroxypropyl cellulose, and 1.5% w/w sodium stearyl fumarate. The ribbons are produced on a roller compactor with roll force between 18 kN/cm and 25 kN/cm, roll speed 6–10 rpm, and gap 2.0–3.0 mm; ribbon density is controlled at 1.20 g/cm³ to 1.35 g/cm³. Milling through a 20-mesh screen generates granules retained between 0.250 mm and 0.841 mm, with fines below 150 µm limited to not more than 30% because higher fines increase weight variability during encapsulation. Capsule filling is performed on an automatic capsule machine with a dosing-disc/tamping-pin system, target fill weight 120 mg in hard gelatin size 2 shells; tamping-pin hardness is adjusted so that plug porosity remains between 0.35 and 0.50. The processing room is maintained at 45–50% RH and 20–25°C because gelatin shells become brittle below 40% RH and soften above 60% RH, producing split caps or retarded dissolution. Granules are tested for flow using USP <1174> with a funnel orifice of 10 mm, and the Carr index is kept below 20. Capsule content uniformity follows USP <905>, disintegration follows USP <701> with a limit of not more than 15 min in 0.1 N hydrochloric acid, and dissolution follows USP <711> Apparatus II at 50 rpm. The terminal finished product is a hard gelatin or hypromellose capsule containing a roller-compacted granulate; the capsule shell and granulate must be individually controlled for moisture because residual water above 2.0% by USP <921> can mobilize the secondary amine hydrochloride and increase related substances during storage. Compatibility studies exclude reducing sugars and high surface-area silicates when the granulate is dried at temperatures above 50°C; published forced degradation data for this specific configuration remains limited, so a formulation-specific compatibility protocol under ICH Q8(R2) is required before commercial scale-up.

Wet Granulation Processing Window for Oral Granules

Wet granulation of the (1S)-4,5-dimethoxy-1-[(methylamino)methyl]benzocyclobutane hydrochloride salt is used for oral granules intended for sachet filling or for downstream tablet compression where dose uniformity must be improved before blending. The granulating fluid is prepared by dispersing hypromellose E5 at 5.0% w/w in purified water; the binder solution is sprayed at 1.2–1.8 kg/min into a 300 L high-shear granulator containing a dry premix of 10.0% w/w API, 45.0% w/w mannitol, 20.0% w/w pregelatinized starch, 4.0% w/w hypromellose E5, and 2.0% w/w sodium starch glycolate. The granulation endpoint is controlled by impeller motor current and time; the target granule moisture before drying is 18–22% by loss on drying. Drying is performed in a fluidised-bed drier with inlet air at 60–70°C, product temperature not exceeding 40°C, and final loss on drying between 1.5% and 2.5% by USP <731>. Dried granules are milled through a 16-mesh screen, and the fraction retained between 0.150 mm and 1.18 mm is used for sachet filling. Granule size distribution is measured by sieve analysis per USP <786>; the limit for particles below 150 µm is not more than 20% to avoid sachet dustiness and dose non-uniformity. Sachet filling is performed on a vertical form-fill-seal line at 1.000 g fill weight with mass variation limits based on USP <905> for unit-dose preparations; the finished oral granules are dispersed in water before administration, and dispersion time is controlled at not more than 3 min in 50 mL of purified water at 25°C. Chemical release testing includes assay, related substances, water content, and chiral purity. The oral granule dosage form carries a compliance obligation under FDA 21 CFR 211.110 for in-process sampling and ICH Q6A for specification setting; because the hydrochloride salt contains a secondary amine, the formulation must avoid high-pH granulating fluids that would deprotonate the amine and increase volatility or phase separation. Published data for wet granulation stability at pH above 6.5 is limited; therefore, the granulating fluid is acidified with hydrochloric acid to pH 4.0–4.5 when compatibility studies show base-catalysed degradation. The terminal finished product is a white to off-white sachet granule with a final moisture content below 2.5% and a labelled storage condition of 25°C/60% RH in aluminium foil sachets with a desiccant pouch.

Aseptic processing of the (1S)-4,5-dimethoxy-1-[(methylamino)methyl]benzocyclobutane hydrochloride salt for injectable solutions begins with the preparation of a sterile filtered bulk in which the hydrochloride salt is dissolved in Water for Injection that has been cooled to 15–25°C and sparged with nitrogen until dissolved oxygen is below 1.0 ppm. The bulk solution is adjusted to pH 4.5–5.0 with 0.1 N hydrochloric acid or 0.1 N sodium hydroxide, and tonicity is adjusted with sodium chloride to 0.9% w/v, giving an osmolality of 280–320 mOsm/kg by USP <785>. The drug substance concentration is adjusted to the label claim and is not allowed to vary by more than ±2.0% from batch record target using a density factor of 1.003 g/mL. The solution is filtered through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane at a differential pressure not exceeding 1.0 bar; the sterilising filter membrane complies with ASTM F838-20 for bacterial retention, and filter integrity is evaluated before and after filtration against the membrane manufacturer's bubble point specification. The holding time for the sterile filtered bulk is limited to 8 h at 20–25°C unless process-specific microbial validation supports a longer period. Filling is performed in a Grade A laminar-airflow zone with Grade B background according to EU GMP Annex 1, using Type I borosilicate glass vials of 10 mL nominal volume and 13 mm chlorobutyl rubber stoppers. The fill volume is 5.0 mL for single-dose vials, and the gravimetric fill weight check is performed every 30 min with acceptance limits of ±2.0%. Sterility is tested by USP <71>, bacterial endotoxins by USP <85>, and particulate matter by USP <788> light obscuration with limits not more than 6000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container. The terminal finished product is a clear, colourless to pale yellow single-dose injectable solution. Terminal sterilisation is not applied because the thermal sensitivity of the chiral secondary amine hydrochloride has not been fully mapped; published data for this specific configuration is limited, and aseptic filtration remains the default regulatory route under ICH Q5A and FDA 21 CFR 211.167.

When Terminal Sterilisation of the Hydrochloride Salt Is Not Feasible, Lyophilisation Supplies the Alternative

Freeze-drying of the (1S)-4,5-dimethoxy-1-[(methylamino)methyl]benzocyclobutane hydrochloride salt in vials is selected when the aqueous solution shows insufficient chemical stability under accelerated storage conditions, particularly when chiral purity or related substances approach specification limits at 25°C/60% RH. The pre-lyophilisation solution contains 4.0% w/v API, 4.0% w/v mannitol as crystalline bulking agent, and 10 mM citrate buffer at pH 4.0. The solution is filled at 5.0 mL into 50 mL Type I glass vials and partially stoppered with lyophilisation closures. Freezing is performed by ramping the shelf from 5°C to -40°C at 0.5°C/min, followed by an annealing step at -20°C for 2 h to crystallise mannitol and prevent vial breakage. Primary drying is conducted at a shelf temperature of -30°C and chamber pressure of 0.15–0.20 mbar for 36–48 h; product temperature is monitored by thermocouples and kept below the collapse temperature determined by freeze-drying microscopy, and published data for this specific formulation is limited, so a conservative thermal safety margin of 2–3°C below collapse is applied. Secondary drying is performed at 25°C and 0.05 mbar for 6 h, yielding a residual moisture content not more than 2.0% by Karl Fischer titration under USP <921>. The lyophilised cake must be white to off-white, retain its shape, and reconstitute in 10 mL Water for Injection within 90 s; after reconstitution, the solution must meet pH 4.0–5.0, osmolality 280–320 mOsm/kg, and particulate matter limits of USP <788>. Vial integrity is verified by dye ingress using USP <1207> or vacuum decay. The terminal finished product is a lyophilised powder for injection that must be stored under refrigerated conditions if stability data demonstrate that moisture or temperature excursions above 25°C increase the total impurity count; the product label carries a reconstitution instruction and a microbial shelf-life assigned according to ICH Q1A(R2) and ICH Q5C.

In fluid-bed granulation of the (1S)-4,5-dimethoxy-1-[(methylamino)methyl]benzocyclobutane hydrochloride salt, the binder solution is sprayed from a top-spray nozzle while heated inlet air simultaneously dries the growing granules, producing a low-density granule with high dispersibility for oral suspension sachets. The dry charge consists of 6.0% w/w API, 60.0% w/w mannitol, 20.0% w/w sorbitol, 4.0% w/w povidone K30, 3.0% w/w sodium starch glycolate, and 2.0% w/w citric acid monohydrate. The binder solution is povidone K30 dissolved at 10% w/w in purified water and sprayed at 80–120 g/min; inlet air temperature is 55–65°C, product temperature is maintained at 30–35°C, and airflow is 80–120 m³/h in a top-spray fluid-bed chamber. Granulation continues until the predicted end-point moisture is 10–12%; final drying continues until loss on drying is not more than 2.0% by USP <731>. The dried granules are passed through a 20-mesh screen and filled at 2.000 g per sachet; sachet mass variation is controlled under USP <905>, and microbial quality is confirmed by USP <61> and USP <62>. Dispersibility is tested by adding the sachet contents to 50 mL of water at 25°C; a uniform suspension must form within 3 min with no visible aggregates larger than 1.0 mm. The terminal finished product is a unit-dose sachet filled with oral suspension granules; the sachet is packaged in aluminium foil with a desiccant and stored at 25°C/60% RH based on stability data generated under ICH Q1A(R2).